Current disease status-First occurrence of the myeloma Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the myeloma Posts on Medivizor

Evaluating the effectiveness and safety of an all-oral combination of ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma undergoing stem cell transplantation.

Evaluating the effectiveness and safety of an all-oral combination of ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma undergoing stem cell transplantation.

Posted by on May 8, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of an all-oral combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone (Decadron) in transplant-eligible patients with newly diagnosed multiple myeloma (MM). The data showed that this combination was effective with manageable side effects in these...

Read More

Adding daratumumab to lenalidomide and dexamethasone therapy for the treatment of patients with newly diagnosed multiple myeloma.

Adding daratumumab to lenalidomide and dexamethasone therapy for the treatment of patients with newly diagnosed multiple myeloma.

Posted by on Dec 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) therapy for patients with newly diagnosed multiple myeloma (MM). The data showed that adding daratumumab to the lenalidomide and dexamethasone (Rd) regimen was safe and improved...

Read More

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Posted by on Sep 12, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effects of administering personalized doses of VCD (bortezomib, cyclophosphamide, and dexamethasone) followed by VTD (bortezomib, thalidomide, and dexamethasone) in older patients with newly diagnosed multiple myeloma (NDMM). The data showed high response rates and safety in these patients. Some background...

Read More

Evaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma

Evaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma

Posted by on Aug 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the outcomes of autologous stem cell transplantation (ASCT) for patients with recurrent multiple myeloma (MM). This study found that long-term outcomes for these patients were promising, especially for patients who had the transplant right away after a first relapse. Some background Multiple myeloma (MM) is a type of...

Read More

Is autologous stem cell transplant safe and effective for patients aged 75 or older with multiple myeloma?

Is autologous stem cell transplant safe and effective for patients aged 75 or older with multiple myeloma?

Posted by on Mar 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the safety and effectiveness of autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM) aged 75 or older. The study found that ASCT was safe and effective for certain patients in this age group. Some background MM is a type of blood cancer that impacts bone marrow. Therapy for...

Read More

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Posted by on Feb 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared a combination therapy of carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone (Decadron), and cyclophosphamide (Cytoxan) to control combination therapies as an alternative treatment regimen in newly diagnosed patients with multiple myeloma (MM).   The authors concluded that this regimen provided very good...

Read More

Long-term follow-up after bortezomib, thalidomide, and dexamethasone treatment followed by double stem cell transplant in patients with multiple myeloma.

Long-term follow-up after bortezomib, thalidomide, and dexamethasone treatment followed by double stem cell transplant in patients with multiple myeloma.

Posted by on Feb 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared long-term outcomes after treatment with bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (Ozurdex) or VTD compared to thalidomide and dexamethasone (TD) followed by double hematopoietic stem cell transplant (HSCT) in patients with newly diagnosed multiple myeloma (MM). The study found...

Read More

Elotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.

Elotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.

Posted by on Oct 10, 2020 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to examine the effectiveness and safety of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone (Decadron) in relapsed or refractory (unresponsive) multiple myeloma (MM). The authors found that there was an improved survival in these patients in the long-term. Some...

Read More

Should maintenance therapy be used in transplant ineligible adults with multiple myeloma?

Should maintenance therapy be used in transplant ineligible adults with multiple myeloma?

Posted by on Sep 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This article was carried out to analyze trials carried out in order to assess the role of maintenance therapy in transplant-ineligible (TI) patients with multiple myeloma (MM) following induction therapy. The authors found that maintenance therapy increases survival without disease worsening in these patients. Some background MM is...

Read More

Can the addition of bortezomib improve treatment results long-term for patients with multiple myeloma?

Can the addition of bortezomib improve treatment results long-term for patients with multiple myeloma?

Posted by on Jun 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined if the addition of bortezomib (Velcade) to treatment with lenalidomide (Revlimid) and dexamethasone (Decadron) could improve treatment results long-term for patients with multiple myeloma (MM). The authors found that patients who received bortezomib had a longer survival long-term. Some background...

Read More

Evaluating isatuximab for patients with recurrent or non-responding multiple myeloma

Posted by on Jan 8, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...

Read More